Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 in a Prostatectomy Model (LUTACT Trial)
Description:
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.
Sponsor:
Thomas Hope
Contacts:
Maya Aslammaya.aslam@ucsf.edu
(415) 514-8987
Government Study Link:
NCT07054346 - Click here to see study onClinicalTrials.gov
225Ac-PSMA-617.
- PSMA
177Lu-PSMA-617
- PSMA
